Therefore, Eg5 is a new possible target for drug development in AD: in particular, prevention of its complete inhibition by Aβ accumulation strengthens brain function, although the presence of deposits in AD brain still represents the main critical point of the disease [103]. The gene discussed is KIF11; the disease is Alzheimer disease.